Trump said he will sign an executive order on "drug price reduction." Tonghua Dongbao: Not affected by the policy in the short term.

On May 11th, local time in the United States, President Trump posted on the social platform Truth Social, stating that on May 12th at 9 a.m., he will sign "one of the most influential executive orders in American history" at the White House. The prices of prescription drugs and pharmaceutical products "will decrease by almost 30% to 80% immediately," as the "most favored nation policy" will require drug prices paid by the United States to be the same as the lowest prices paid globally. On May 12th, a domestic insulin company in China, Tonghua Dongbao, responded that the company currently does not sell any products in the United States and will not be affected by this policy in the short term. The company has technological barriers to scale production, and in the future, with the promotion of insulin products such as dandelion, ganjing, and laifu in the United States, the company is expected to still bring considerable profit space due to this advantage. Additionally, the drug approval system in the United States is highly recognized in developing countries, and the company hopes to accelerate the registration approval process in emerging markets and some countries participating in the "Belt and Road" initiative through approval in the United States to quickly cover relevant markets.